Superselective Intra-arterial Chemotherapy Treatment for Retinoblastoma- 5 Year Results From Turkey
Completed
- Conditions
- Retinoblastoma
- Interventions
- Drug: intra-arterial administration of melphalan
- Registration Number
- NCT03935074
- Lead Sponsor
- Istanbul University - Cerrahpasa (IUC)
- Brief Summary
Retrospective review of 5-year long term outcomes of superselective intra-arterial chemotherapy treatment in retinoblastoma in a single institute.
The treatment outcomes, globe salvage rates and complications of superselective intra-arterial chemotherapy both for treating naive patients (primary treatment group) and for patients who received systemic chemotherapy previously (secondary treatment group) were evaluated.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
- patients diagnosed with unilateral/bilateral retinoblastoma
Exclusion Criteria
- patients with trilateral retinoblastoma
- extraoculer involvement
- patients with blood dyscrasias, bleeding and clotting disorders
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description group 1 intra-arterial administration of melphalan Patients who received intra-arterial chemotherapy as a first line treatment group 2 intra-arterial administration of melphalan Patients who received intra-arterial chemotherapy as a salvage treatment after systemic chemotherapy
- Primary Outcome Measures
Name Time Method globe salvage 2-5 years globe salvage rate after superselective intra-arterial chemotherapy treatment for retinoblastoma
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Istanbul University Cerrahpasa School of Medicine Ophthalmology Department
🇹🇷Istanbul, Turkey